{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:10:07Z","timestamp":1749597007102,"version":"3.41.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["6 NU17CE925012-03-01"],"award-info":[{"award-number":["6 NU17CE925012-03-01"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.josat.2025.209719","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T22:00:54Z","timestamp":1746741654000},"page":"209719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Counseling as a complement to buprenorphine treatment for opioid use disorder: A retrospective observational study of patient outcomes"],"prefix":"10.1016","volume":"175","author":[{"given":"Tianjie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md.","family":"Noor-E-Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Mahmudul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard D.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2025.209719_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004147.pub4","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","author":"Amato","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"author":"American Society of Addiction Medicine","key":"10.1016\/j.josat.2025.209719_bb0010"},{"key":"10.1016\/j.josat.2025.209719_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209719_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-022-00299-1","article-title":"Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community","volume":"17","author":"Biondi","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2025.209719_bb0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drugalcdep.2014.02.013","article-title":"A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification","volume":"138","author":"Brigham","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209719_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100191","article-title":"Emergency-department initiated buprenorphine: Impact on quality of life","volume":"9","author":"Carroll","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.josat.2025.209719_bb0035"},{"key":"10.1016\/j.josat.2025.209719_bb0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention strategies for medications for opioid use disorder in adults: A rapid evidence review","volume":"15","author":"Chan","year":"2021","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2025.209719_bb0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/MLR.0000000000001165","article-title":"Chronic disease medication adherence after initiation of buprenorphine for opioid use disorder","volume":"57","author":"Chang","year":"2019","journal-title":"Medical Care"},{"author":"Connolly","key":"10.1016\/j.josat.2025.209719_bb0050"},{"key":"10.1016\/j.josat.2025.209719_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2025.209719_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.josat.2025.209719_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109680","article-title":"Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population","volume":"241","author":"Hallowell","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209719_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108416","article-title":"Patterns of patient discontinuation from buprenorphine\/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts","volume":"131","author":"Hasan","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209719_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/00952990.2022.2065638","article-title":"Long-term patient outcomes following buprenorphine\/naloxone treatment for opioid use disorder: A retrospective analysis in a commercially insured population","volume":"48","author":"Hasan","year":"2022","journal-title":"American Journal of Drug and Alcohol Abuse"},{"author":"Henley","key":"10.1016\/j.josat.2025.209719_bb0080"},{"key":"10.1016\/j.josat.2025.209719_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2025.209719_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2010.12.024","article-title":"Transitioning opioid-dependent patients from detoxification to long-term treatment: Efficacy of intensive role induction","volume":"117","author":"Katz","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209719_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2025.209719_bb0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2025.209719_bb0105","doi-asserted-by":"crossref","DOI":"10.31478\/202004b","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: Strategies to address key barriers within the treatment system","author":"Madras","year":"2020","journal-title":"NAM Perspectives."},{"key":"10.1016\/j.josat.2025.209719_bb0110","article-title":"Opioid substitution treatment is linked to reduced risk of death in opioid use disorder","volume":"357","author":"Manhapra","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2025.209719_bb0115","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2025.209719_bb0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209719_bb0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209719_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s11414-023-09841-8","article-title":"Outcomes associated with treatment with and without medications for opioid use disorder","volume":"50","author":"Mutter","year":"2023","journal-title":"The Journal of Behavioral Health Services & Research"},{"author":"National Committee for Quality Assurance","key":"10.1016\/j.josat.2025.209719_bb0135"},{"author":"National Institute on Drug Abuse","key":"10.1016\/j.josat.2025.209719_bb0140"},{"key":"10.1016\/j.josat.2025.209719_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: An analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209719_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jsat.2019.06.010","article-title":"A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings","volume":"104","author":"Presnall","year":"2019","journal-title":"Journal of Substace Abuse Treatment"},{"author":"RAND","key":"10.1016\/j.josat.2025.209719_bb0155"},{"key":"10.1016\/j.josat.2025.209719_bb0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jphys.2016.05.008","article-title":"Charlson comorbidities index","volume":"62","author":"Roffman","year":"2016","journal-title":"Journal of Physiotherapy"},{"key":"10.1016\/j.josat.2025.209719_bb0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.josat.2025.209719_bb0170","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2025.209719_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108774","article-title":"Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes","volume":"139","author":"Samples","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209719_bb0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1060028017751913","article-title":"Treatment persistence among insured patients newly starting buprenorphine\/naloxone for opioid use disorder","volume":"52","author":"Shcherbakova","year":"2018","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.josat.2025.209719_bb0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1196\/annals.1441.030","article-title":"Chronic stress, drug use, and vulnerability to addiction","volume":"1141","author":"Sinha","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.josat.2025.209719_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.3285","article-title":"Expert panel consensus on state-level policies to improve engagement and retention in treatment for opioid use disorder","volume":"3","author":"Smart","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2025.209719_bb0195","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.josat.2025.209719_bb0200"},{"key":"10.1016\/j.josat.2025.209719_bb0205","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","article-title":"Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients","volume":"46","author":"Tkacz","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"author":"US Department of Health & Human Services","key":"10.1016\/j.josat.2025.209719_bb0210"},{"author":"Vital Strategies","key":"10.1016\/j.josat.2025.209719_bb0215"},{"key":"10.1016\/j.josat.2025.209719_bb0220","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.josat.2025.209719_bb0225","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209719_bb0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine","volume":"74","author":"Weinstein","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209719_bb0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.20230808","article-title":"Defining discontinuation for buprenorphine treatment: Implications for quality measurement","volume":"181","author":"Williams","year":"2024","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2025.209719_bb0240","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/add.15189","article-title":"Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: A retrospective cohort study","volume":"116","author":"Zhou","year":"2021","journal-title":"Addiction"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T22:53:28Z","timestamp":1749596008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"alternative-id":["S2949875925000980"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209719","relation":{},"ISSN":["2949-8759"],"issn-type":[{"type":"print","value":"2949-8759"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Counseling as a complement to buprenorphine treatment for opioid use disorder: A retrospective observational study of patient outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209719"}}